Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adherium Ltd. ( (AU:ADR) ) has issued an announcement.
Adherium reported a strong March-quarter performance in its U.S.-focused remote patient monitoring business, with recurring subscription revenues rising 101% quarter-on-quarter to a record $344,000 and cumulative RPM device shipments and activations reaching 3,617 and 2,622 respectively. The company now has a pipeline of 40,000 insurance-verified, compatible inhaler patients and is targeting 10,000 RPM device shipments by the end of 2026, supported by new 2026 CPT reimbursement codes and growing real-world data assets that underpin its push toward larger value-based care contracts.
Quarterly cash receipts from customers fell to $228,000 due to the absence of a prior milestone payment from AstraZeneca, but Adherium expects the next study payment in July 2026, helping support near-term cash flow. Management highlights three consecutive quarters of accelerating RPM growth and expanding clinic relationships as evidence that its operational infrastructure is scaling, positioning the company to leverage its proprietary longitudinal patient dataset in future clinical, commercial and payer engagements.
More about Adherium Ltd.
Adherium Ltd. is an Australia-based digital health company focused on respiratory disease management through its US FDA-cleared Hailie Smartinhaler platform. The business provides remote patient monitoring services that connect chronic respiratory patients to clinical care teams, with a strategic focus on the U.S. market where reimbursement frameworks support its recurring subscription model.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.75M
See more insights into ADR stock on TipRanks’ Stock Analysis page.